You are here
Medicines Safety Update, Volume 4, Number 1, February 2013
Medicines Safety Update is the medicines safety bulletin of the Therapeutic Goods Administration (TGA).
In this issue
Immunomodulatory medicines have emerged as a class of medicines associated with the development of progressive multifocal leukoencephalopathy. Awareness of risk factors and early recognition of symptoms is important as early diagnosis is likely to improve the prognosis.1
What is PML?
Progressive multifocal leukoencephalopathy (PML) is a rare, but often fatal, demyelinating disease of the central nervous system. PML is caused by lytic infection of oligodendrocytes and astrocytes resulting in multiple areas of demyelination in the central nervous system.
PML lesions are typically asymmetrical demyelinated plaque areas with irregular borders, surrounded by macrophages and irregular astrocytes with large, multiple nuclei.2 On magnetic resonance imaging (MRI), the lesions usually do not show oedema, mass effect or gadolinium enhancement, which are common in multiple sclerosis.2
Patients with PML can have a variety of symptoms including muscle weakness, sensory deficit, cognitive dysfunction, language impairment and/or coordination and gait difficulties.3
What causes PML?
PML is caused by a human polyomavirus, the JC virus. The virus was named after the patient from whom it was initially cultivated, John Cunningham. Approximately 50% of the world's population are infected with the virus by the time they reach age 20, although most remain asymptomatic.4 After initial virus infection, the virus remains quiescent in the kidneys, bone marrow and lymphoid tissue.3
In immunocompromised individuals the quiescent virus can reactivate, enter the bloodstream and then gain entry to the central nervous system where it infects oligodendrocytes and astrocytes. Infection of these cells leads to cell death, and the resulting demyelination produces the neurological signs and symptoms of PML.5
Viruses isolated from the brains of individuals with PML have a genomic rearrangement in the regulatory region that is not found in the strains responsible for initial infection.4,5
What are the risk factors?
Patients who are immunosuppressed or have a malfunction of the immune system are at higher risk of developing PML. Cell-mediated immunity disorders are the major immunological disorders that predispose individuals to the development of PML.4
PML cases have been reported in patients with HIV, lymphoproliferative disorders, malignancies, patients on immunosuppressive therapy after solid organ transplantation and in rheumatic diseases such as systemic lupus erythematosus.6,7
Immunosuppressive medications that have been associated with PML include cyclophosphamide, corticosteroids, mycophenolate mofetil and monoclonal antibodies including natalizumab (Tysabri), rituximab (Mabthera) and alemtuzumab (MabCampath).8 The Australian Product Information for both rituximab and natalizumab carries a black box warning on the risk of PML.
How is PML diagnosed?
Diagnosis should be considered in any patient with risk factors who presents with progressive neurological signs or symptoms and has MRI evidence of multiple characteristic lesions. The early signs of PML are often related to cognitive dysfunction, manifesting as mental slowness, disorientation and behavioural changes.2 Motor and sensory disturbance, characterised by lack of coordination, gait disturbance, ataxia, hemiparesis or visual deficits may also be found at the time of presentation.2 Seizures, language difficulties and headaches can occur but are less common. These signs and symptoms progress over the course of a few weeks and death can occur weeks to months after diagnosis.
The diagnosis can be confirmed by detection of JC virus DNA or proteins using in situ hybridisation or immunohistochemistry on a brain biopsy sample, or by detection of JC virus DNA in the cerebrospinal fluid by quantitative polymerase chain reaction.3 However, a negative polymerase chain reaction result does not exclude the diagnosis of PML, particularly early in the disease.
How many cases have been reported?
A search of the Australian and New Zealand adverse event databases found 28 reports of PML (Table). Many of these cases had multiple risk factors including prior or concomitant immunosuppression therapies, underlying disease and chemotherapy. The majority of reports were associated with the monoclonal antibodies, rituximab and natalizumab. However, this may be due to greater awareness of PML in association with these particular medicines.
|Medicine||No. of reports|
|* Co-suspect medicines in same report. # Co-suspect medicines in same report.|
How is PML treated?
Improved chance of survival is associated with early diagnosis, younger age at diagnosis and if the disease is limited to one lobe of the brain.1
Current treatment of PML is limited and is generally supportive in nature.
The current treatment strategy for PML in HIV-negative patients is to restore the host adaptive immune response by stopping or decreasing immunosuppression.3 There are currently no specific antiviral drugs for the JC virus.
Recovery of the immune system can trigger immune reconstitution inflammatory syndrome (IRIS). In HIV-negative patients with PML-IRIS, the current treatment is corticosteroids to reduce the inflammatory response.3
- PML is a rare but potentially fatal disease
- Patients with compromised immune systems due to immunomodulatory medicines or disease are at risk of developing PML
- A diagnosis of PML should be considered for any patient with risk factors who presents with progressive neurological signs or symptoms
- Early diagnosis is associated with an improved chance of survival
Conjointly prepared by the TGA and Medsafe (the New Zealand Medicines and Medical Devices Safety Authority)
- Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumabassociated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-704.
- Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
- Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425-37.
- Berger JR, Khalili K. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 2011;12:495-503.
- Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010;68:271-4.
- Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:3761-5.
- Holman RC, Torok TJ, Belay ED, Janssen RS, Schonberger LB. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 1998;17:303-9.
- Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 2010;66:199-206.
Health professionals are advised that the Product Information for thyroxine has recently been updated to include a precaution about the increased risk of osteoporotic fracture associated with excessive thyroxine doses. Control of hypothyroidism should be monitored regularly, especially in the elderly, and the thyroxine dose adjusted accordingly.
Chronic hyperthyroidism promotes bone turnover, characterised by increases in bone resorption and in urinary excretion of calcium and phosphorus. Increased bone resorption may result in osteoporosis and an increased risk of fracture. A similar risk appears to exist for hypothyroid patients receiving higher-than-needed doses of thyroxine. The elderly may be at particularly increased risk, since thyroxine replacement needs decrease with age, and age is an additional risk factor for osteoporosis.1
Fracture risk with thyroxine replacement therapy
Two recent large studies have examined the risk of fracture in patients on long-term thyroxine replacement. A nested case-control study in 213 511 Canadian thyroxine users aged over 70 followed patients for a mean of 3.8 years.1 Thyroxine use was classified as high (>93 microgram), medium (44-93 microgram) or low dose (<44 microgram daily) based on cumulative dose over the preceding 12 months. Among current (at the time of fracture) thyroxine users, high thyroxine doses were associated with a 3.5-fold increased risk of fracture, and medium doses with a 2.6-fold increased risk, compared to low doses. Both these results were statistically significant. The study did not check for appropriateness of thyroxine use by measuring thyroid stimulating hormone (TSH) levels.
An observational cohort study in 17 684 Scottish thyroxine users aged 18 and over, with a median follow-up of 4.5 years, classified patients according to their mean TSH level over time, into suppressed (TSH ≤0.03 mU/L), low (0.04-0.4 mU/L), normal (0.4-4.0 mU/L) and high (>4.0 mU/L).2 Compared to patients with normal TSH, there was a statistically significant two-fold increased risk of hospitalisation or death due to osteoporotic fracture in patients with suppressed TSH. There was no significant increase in risk for patients with a low (but not suppressed) TSH.
Although neither study measured both thyroxine and TSH levels, each found an association between either high or excessive (as measured by TSH suppression) thyroxine dose and fracture. As well as increasing the risk of osteoporosis, excess thyroxine may also increase the risk of falls secondary to arrhythmia or muscle weakness, particularly in the elderly.1
Information for health professionals
Health professionals are advised that the Product Information for thyroxine (Oroxine, Eutroxsig) has recently been updated with a new precaution about the effects of thyroxine on bone mineral density. It is recommended that patients receiving thyroxine are given the minimum dose necessary to achieve the desired clinical and biochemical response. Prescribers should keep in mind that replacement thyroxine needs decrease in the elderly and serum TSH should be monitored regularly and thyroxine doses adjusted accordingly. The risk of fracture may be greater in patients with other risk factors for osteoporosis, including postmenopausal women, those with a family history or past history of fracture or osteoporosis, smokers, and patients with vitamin D deficiency.
- Turner MR, Camacho X, Fischer HD, Austin PC, Anderson GM, Rochon PA, et al. Levothyroxine dose and risk of fracture in older adults: nested case-control study. BMJ 2011;342:d2238.
- Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-193.
The use of oral bowel cleansing products is part of the preparation for a number of medical, diagnostic and surgical procedures. These products create a cathartic effect by osmotic action, resulting in a transfer of fluid and electrolytes to the gut lumen. Marked dehydration, electrolyte abnormalities and associated complications may occur as a result in otherwise well patients. The TGA has previously alerted prescribers to the risk of severe electrolyte disturbances in association with the use of sodium picosulfate-containing products.1
Since January 2002 the TGA has received a total of 51 adverse event reports for these products, of which 18 were reports of serious electrolyte disturbances. One of these reports was of a 60-year-old patient who experienced a cardiac arrest, one was of a 50-year-old patient who sustained permanent hypoxic brain damage as a result of serious adverse events following hyponatraemia, and a third report was of a 38-year-old who developed hyponatraemic encephalopathy.
While it is known that the elderly, the frail and those with cardiac failure or renal impairment are potentially at higher risk of an adverse event, health professionals are reminded that serious adverse events can occur in patients under the age of 60 years who are otherwise fit and healthy, and that this should be considered when prescribing/dispensing these products. All patients should be reminded of the importance of hydration and electrolyte replacement while taking these products and to seek medical attention if they experience any signs of severe dehydration, such as excessive thirst, dizziness, confusion and decreased urine output or dark coloured urine.
- Electrolyte disturbances with sodium picosulfate bowel cleansing products. Aust Adv Drug React Bull 2002;21:1.
The TGA encourages the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies.
We particularly request reports of:
- all suspected reactions to new medicines
- all suspected medicines interactions
- suspected reactions causing death, admission to hospital or prolongation of hospitalisation, increased investigations or treatment, or birth defects.
Reports may be submitted:
- using the 'blue card' available from the TGA website and with the August issue of Australian Prescriber
- online at www.tga.gov.au
- by fax to (02) 6232 8392
- by email to ADR.Reports@tga.gov.au
For more information about reporting, visit www.tga.gov.au or contact the TGA's Office of Product Review on 1800 044 114.
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2013
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to firstname.lastname@example.org.
For the latest safety information from the TGA, subscribe to the TGA Safety Information email list via the TGA website.
For correspondence or further information about Medicines Safety Update, contact the TGA's Office of Product Review at ADR.Reports@tga.gov.au or 1800 044 114.
Medicines Safety Update is written by staff from the Office of Product Review.
Editor: Dr Katherine Gray
Principal Medical Advisor: Dr Tony Gill (acting)
Contributors to this issue include Dr Claire Behm, Dr Richard Hill, Dr Pamela Whalan